Skip to main content
. Author manuscript; available in PMC: 2022 Sep 28.
Published in final edited form as: Cancer Cell. 2022 Aug 18;40(9):939–956.e16. doi: 10.1016/j.ccell.2022.07.011

Figure 7. Glioma cells use divergent routes for pyrimidine and purine nucleotide synthesis under physiologic conditions.

Figure 7.

(A) Steady-state quantification of the indicated metabolites in BT054 GSCs treated with 10 nM BAY 2402234, 5 μM lometrexol, or DMSO (n = 8 per condition).

(B) Pathways targeted by BAY 2402234 (BAY) and lometrexol (Lom).

(C) 15N stable isotope tracing assays in BT054 and TS516 GSC lines (n = 3).

(D) Select pathways using intermediates derived from de novo pyrimidine nucleotide synthesis.

(E and F) Volcano plots of metabolites in HOG-EV (E) or HOG-R132H (F) cells treated with 10 nM BAY 2402234 relative to DMSO (n = 4).

(G) Ratio of pyrimidine (dTTP, dCTP) to purine (dATP) deoxynucleotide triphosphate (dNTP) pools in cells shown in (E and F). For all panels, data are means ± SEM; *p < 0.05, ***p < 0.001. n.s., not significant. Two-tailed p values were determined by unpaired t test.